Fig. 1: EZH2 shows a noncanonical function in TNBC.
From: Noncanonical association of EZH2 with E2F1 promotes tumor proliferation through chromatin remodeling
a The expression levels of PRC2 components in human breast tumors (n = 1116) and normal breast tissues (n = 113) from the TCGA BRCA dataset. b The expression of PRC2 components in TNBC (n = 115) and non-TNBC (n = 604) groups from the TCGA BRCA dataset. All data represent mean ± s.e.m.; **P ≤ 0.01, ***P ≤ 0.001, N.S., not significant. c The relative protein levels of PRC2 components in TNBC (n = 11) and non-TNBC (n = 94) groups using isobaric tags for relative and absolute quantitation-based quantification from the TCGA Breast Cancer Proteomics Study dataset. TNBC groups were selected based on low expression levels of ERBB2, ESR1 and PGR, defined as less than −1. To assess group differences in protein expression, the Wilcoxon rank-sum test was applied. All data represent mean ± s.e.m.; *P ≤ 0.05. d The effect of EZH2 or SUZ12 knockdown on the cell growth in MDA-MB-231 cells. The inset shows the protein levels of EZH2 and SUZ12. e The effect of EZH2 or SUZ12 knockdown on the cell growth in MCF7 cells. The inset shows the protein levels of EZH2 and SUZ12. shCtrl indicates cells transduced with a control vector. f The effect of GSK126 (1–5 μM) on the cell growth in MDA-MB-231 cells (n = 3; mean ± s.d.; unpaired two-tailed Student’s t-test). The inset shows the dose-dependent effect on the protein levels of EZH2 and H3K27me3.
